Sample size and statistical analyses
The sample size was selected to allow estimation of the key PK parameters (AUC and A total of 64 participants were planned to be randomized to receive GSK3772847 or placebo for a total of 18 evaluable participants on GSK3772847 in cohorts 1 and 2, six Japanese participants in cohort 3, and six Chinese participants in cohort 4. While this study was not designed to determine bioequivalence, the sample size for the critical evaluations of dose and injection site comparisons were in line with appropriate guidance, where the minimum number of participants should not be smaller than 12, (when combined across both doses).